Evidence map›Paper›PMID 39362718›Full record

ReviewClinics in liver disease2024

Current Pharmacotherapy and Nutrition Therapy of Alcohol-Associated Liver Disease.

Josiah E Hardesty, Craig J McClain

Abstract readReview
In one paragraph

Review in Clinics in liver disease, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Article
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Josiah E HardestyDepartment of Pharmacology and Toxicology, University of Louisville School of Medicine, Louisville, KY, USA; Division of Gastroenterology, Hepatology, and Nutrition, Department of Medicine, University of Louisville, Louisville, KY, USA.
Craig J McClainDepartment of Pharmacology and Toxicology, University of Louisville School of Medicine, Louisville, KY, USA; Division of Gastroenterology, Hepatology, and Nutrition, Department of Medicine, University of Louisville, Louisville, KY, USA; University of Louisville Alcohol Center, University of Louisville School of Medicine, Louisville, KY, USA; Robley Rex Veterans Medical Center, Louisville, KY, USA; University of Louisville Hepatobiology & Toxicology Center, University of Louisville School of Medicine, Louisville, KY, USA. Electronic address: Craig.mcclain@louisville.edu.

Funding

Role of oxidized linoleic acid metabolites in the pathogenesis of alcoholic liver diseaseP20GM113226 · NIGMS · UNIVERSITY OF LOUISVILLE · PI MCCLAIN, CRAIG J. · 2016 to 2025
$24.1M
The Role of Nutrition in the Development/Progression of Alcohol-Induced Organ InjuryP50AA024337 · NIAAA · UNIVERSITY OF LOUISVILLE · PI CRAIG J. MCCLAIN · 2016 to 2026
$17.9M
Integrated therapies for alcohol use and ALD (ITAALD) Network -UofL Clinical CenterU01AA026980 · NIAAA · UNIVERSITY OF LOUISVILLE · PI CRAIG J. MCCLAIN, Ashwani K Singal · 2018 to 2026
$2.9M
Mechanisms for alcohol induced gut barrier dysfunction in ALDR01AA023681 · NIAAA · UNIVERSITY OF LOUISVILLE · PI MCCLAIN, CRAIG J. · 2014 to 2018
$1.6M
Restoration and preservation of hepatic cardiolipin levels promotes liver regeneration in AHR00AA030627 · NIAAA · UNIVERSITY OF LOUISVILLE · PI Josiah E Hardesty · 2024 to 2026
$732k
Pilot Trial UO1 DUR-928U01AA026934 · NIAAA · UNIVERSITY OF LOUISVILLE · PI MCCLAIN, CRAIG J. · 2018 to 2022
$356k
Inflammation Resolving Lipid Mediators: Novel Therapy for Alcohol AssociatedLiver DiseaseI01CX002219 · VA · LOUISVILLE VA MEDICAL MEDICAL CENTER · PI CRAIG J. MCCLAIN · 2023 to 2026
–
CSRD VA I01 CX002219NIAAA NIH HHS L70 AA027913NIAAA NIH HHS P50 AA024337NIAAA NIH HHS R00 AA030627NIAAA NIH HHS R01 AA023681NIAAA NIH HHS U01 AA026934NIAAA NIH HHS U01 AA026980NIGMS NIH HHS P20 GM113226
6 · The paper itself

Abstract

Patients with alcohol-associated liver disease (ALD) consume large amounts of empty calories and are at risk for malnutrition. Malnutrition can present with micro- or macro-nutrient deficiencies. The standard-of-care drug treatment for severe alcohol-associated hepatitis (AH) is corticosteroids. While still in the standard treatment there are limitations in efficacy and certain patients do not respond to treatment (Lille score ≥.45). This article will focus on important concepts related to nutrition and ALD and on recent findings on predicting corticosteroid response and prognosis for AH patients.

Indexed as

Liver Diseases, AlcoholicMalnutritionAdrenal Cortex HormonesHepatitis, AlcoholicHumansNutritional SupportNutrition TherapyAdrenal Cortex HormonesAlcohol associated hepatitisAlcohol-associated liver diseaseMalnutritionNon-respondersNutrition support corticosteroids

Identifiers

PMID39362718
PMCPMC11529778

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.